Selected Publications
Verbeke R, Lore K, Hogan MJ, Pardi N.*, * corresponding author: Innate immune mechanisms of mRNA vaccines Immunity : 2022.
McMahon M, O'Dell G, Tan J, Sárközy A, Vadovics M, Carreño JM, Puente-Massaguer E, Muramatsu H, Bajusz C, Rijnink W, Beattie M, Tam YK, Kirkpatrick Roubidoux E, Francisco I, Strohmeier S, Kanekiyo M, Graham BS, Krammer F, Pardi N.*, * corresponding author: Assessment of a quadrivalent nucleoside-modified mRNA vaccine that protects against group 2 influenza viruses Proc Natl Acad Sci U S A : 2022.
Carreño JM, Singh G, Tcheou J, Srivastava K, Gleason C, Muramatsu H, Desai P, Aberg JA, Miller RL, Study Group P, Pardi N, Simon V, Krammer F.: mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulations Vaccine : 2022.
Li D, Martinez DR, Schäfer A, Chen H, Barr M, Sutherland LL, Lee E, Parks R, Mielke D, Edwards W, Newman A, Bock KW, Minai M, Nagata BM, Gagne M, Douek DC, DeMarco CT, Denny TN, Oguin TH 3rd, Brown A, Rountree W, Wang Y, Mansouri K, Edwards RJ, Ferrari G, Sempowski GD, Eaton A, Tang J, Cain DW, Santra S, Pardi N, Weissman D, Tomai MA, Fox CB, Moore IN, Andersen H, Lewis MG, Golding H, Seder R, Khurana S, Baric RS, Montefiori DC, Saunders KO, Haynes BF.: Breadth of SARS-CoV-2 neutralization and protection induced by a nanoparticle vaccine Nat Commun : 2022.
Jitthamstaporn S, Inthong R, Audomsun D, Chanasit S, Thanasarnthungcharoen C, Lin PJC, Weissman D, Pardi N, Jacquet A.: Nucleoside-modified mRNA vaccines yield robust blocking antibody responses against major house dust mite allergens Allergy : 2022.
Wisitrasameewong W, Champaiboon C, Surisaeng T, Sa-Ard-Iam N, Freire M, Pardi N, Pichyangkul S, Mahanonda R.: The Impact of mRNA Technology in Regenerative Therapy: Lessons for Oral Tissue Regeneration J Dent Res : 2022.
Pardi N*, Carreño JM, O'Dell G, Tan J, Bajusz C, Muramatsu H, Rijnink W, Strohmeier S, Loganathan M, Bielak D, Sung MMH, Tam YK, Krammer F, McMahon M., * corresponding author: Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses Nat Commun : 2022.
Muramatsu H, Lam K, Bajusz C, Laczkó D, Karikó K, Schreiner P, Martin A, Lutwyche P, Heyes J, Pardi N.*, * corresponding author: Lyophilization provides long-term stability for a lipid nanoparticle-formulated nucleoside-modified mRNA vaccine Mol Ther : 2022.
Parhiz H, Brenner JS, Patel P, Papp TE, Shahnawaz H, Li Q, Shi R, Zamora M, Yadegari A, Marcos-Contreras OA, Natesan A, Pardi N, Shuvaev VV, Kiseleva R, Myerson J, Uhler T, Riley RS, Han X, Mitchell MJ, Lam K, Heyes J, Weissman D, Muzykantov V.: Added to pre-existing inflammation, mRNA-lipid nanoparticles induce inflammation exacerbation (IE) J Control Release : 2022.
Mu Z, Wiehe K, Saunders KO, Henderson R, Cain DW, Parks R, Martik D, Mansouri K, Edwards RJ, Newman A, Lu X, Xia SM, Eaton A, Bonsignori M, Montefiori D, Han Q, Venkatayogi S, Evangelous T, Wang Y, Rountree W, Korber B, Wagh K, Tam Y, Barbosa C, Alam SM, Williams WB, Tian M, Alt FW, Pardi N, Weissman D, Haynes BF.: mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice Cell Rep : 2022.
Academic Contact Information
476A Stemmler Hall
Philadelphia,
PA
19104
Phone: 215-746-6552